Theravance Biopharma (TBPH) Shares Outstanding (Diluted Average) (2019 - 2026)

Theravance Biopharma (TBPH) has 8 years of Shares Outstanding (Diluted Average) data on file, last reported at $51.3 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $51.3 million, up 3.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.3 million (up 3.16% YoY), and the FY2024 annual result was $48.8 million, down 11.67% from the prior year.
• Shares Outstanding (Diluted Average) rose to $51.3 million in Q1 2026 per TBPH's latest filing, from $50.7 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $75.8 million in Q2 2022 and troughed at $48.3 million in Q1 2024.
• A 5-year average of $58.2 million and a median of $52.4 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) increased 16.67% in 2022, then sank 30.66% in 2023.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $73.6 million in 2022, then slipped by 24.85% to $55.3 million in 2023, then fell by 11.67% to $48.8 million in 2024, then grew by 3.76% to $50.7 million in 2025, then increased by 1.17% to $51.3 million in 2026.
• Business Quant data shows TBPH's Shares Outstanding (Diluted Average) at $51.3 million in Q1 2026, $50.7 million in Q2 2025, and $49.7 million in Q1 2025.